Fate Therapeutics Amasses More Academic Stem Cell IP with Children's Hospital Boston Deal | GenomeWeb

Fate Therapeutics, a stem cell therapeutics company founded in 2007 on technology licensed from several US academic and research institutions, said last week that it has bolstered its patent portfolio by exclusively licensing intellectual property from the lab of one of its scientific co-founders.

The IP, licensed primarily from Children's Hospital Boston but also covering technology developed by a researcher from Massachusetts General Hospital, is related to compositions and methods for supporting hematopoietic stem cells, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.